ALLO Allogene Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1737287 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-26.7%
TTM net income YoY22.1%
TTM EPS YoY36.8%
Revenue 3-yr CAGR-91.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,241,813.6%
Net margin-1,170,863.6%
FCF margin-913,609.1%
EBITDA margin-1,179,818.2%
Returns
ROE-55.1%
ROA-43.2%
ROIC (approx.)-57.1%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets23.1%
Debt / equity0.00x
Current ratio8.54x
Interest coverage-1,509.39x
Cash quality & payout
Operating cash flow / net income0.78x
Accruals ratio-9.6%
Payout ratio—
Capex / revenue3,154.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $4.64M | — | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $41.93M | $30.72M | $32.00M | $28.63M | $31.16M | $40.16M | $50.20M | $44.97M |
| SG&A expense | $12.86M | $20.84M | $14.09M | $13.77M | $13.74M | $14.28M | $14.99M | $15.52M |
| Operating income | -$54.79M | -$46.92M | -$46.09M | -$42.40M | -$44.90M | -$56.82M | -$65.19M | -$60.49M |
| Interest expense | $379,000 | $343,000 | $300,000 | $313,000 | $344,000 | $268,000 | $150,000 | $81,000 |
| Net income | -$50.37M | -$42.68M | -$42.61M | -$38.81M | -$41.40M | -$50.94M | -$59.73M | -$59.94M |
| EBITDA | -$52.21M | -$44.27M | -$43.22M | -$39.35M | -$41.80M | -$53.71M | -$62.09M | -$57.26M |
| EPS (basic) | -0.15 | -0.13 | -0.18 | — | -0.19 | -0.23 | -0.28 | — |
| EPS (diluted) | -0.15 | -0.13 | -0.18 | — | -0.19 | -0.23 | -0.28 | — |
| Weighted avg. shares (diluted) | 346.09M | 328.93M | 240.29M | — | 222.04M | 218.93M | 215.36M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $29.27M | $38.63M | $30.31M | $51.69M | $48.11M | $62.62M | $52.75M | $85.51M |
| Short-term investments | $263.69M | $293.98M | $236.58M | $198.52M | $214.38M | $220.79M | $237.59M | $217.26M |
| Current assets | $299.83M | $340.00M | $273.29M | $257.75M | $260.72M | $282.65M | $291.58M | $303.39M |
| PP&E, net | $64.82M | $67.38M | $70.02M | $72.84M | $75.90M | $78.86M | $82.99M | $86.06M |
| Total assets | $511.32M | $550.09M | $395.96M | $415.90M | $439.77M | $470.59M | $507.98M | $548.71M |
| Current liabilities | $38.50M | $31.73M | $28.33M | $32.51M | $31.83M | $31.68M | $30.02M | $35.52M |
| Total liabilities | $118.77M | $113.92M | $117.08M | $123.36M | $124.44M | $126.03M | $122.59M | $126.53M |
| Shareholders' equity | $392.55M | $436.18M | $278.88M | $292.54M | $315.33M | $344.56M | $385.39M | $422.18M |
| Shares outstanding | 346.28M | 345.35M | 244.82M | 229.41M | 223.16M | 220.13M | 218.60M | 212.21M |
| Cash flow statement | ||||||||
| Operating cash flow | -$36.12M | -$32.00M | -$12.91M | -$27.60M | -$29.69M | -$39.03M | -$52.93M | -$36.70M |
| Capital expenditure | $25,000 | $150,000 | $9,000 | $0 | $243,000 | $44,000 | $99,000 | $257,000 |
| Free cash flow | -$36.14M | -$32.15M | -$12.92M | -$27.60M | -$29.93M | -$39.07M | -$53.03M | -$36.95M |
| Investing cash flow | $26.12M | -$147.56M | -$29.59M | $33.61M | $11.94M | $43.84M | $6.18M | $54.93M |
| Financing cash flow | $646,000 | $187.87M | $21.12M | $7.86M | $3.24M | $5.07M | $13.99M | $5.74M |
| Depreciation & amortization | $2.59M | $2.65M | $2.87M | $3.06M | $3.10M | $3.11M | $3.10M | $3.23M |
| Stock-based compensation | $7.03M | $12.44M | $8.27M | $8.13M | $8.65M | $8.69M | $12.18M | $12.87M |
Free plan shows the latest 8 periods; Pro shows all 35 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.